The funding is supporting Milocron Therapeutics, a company closely involved in the FIT project and established to help translate this research from the laboratory into a clinically available therapy. By bringing together scientific research, development, and the steps needed for clinical application, Milocron plays an important role in moving the FIT approach closer to patients.

Following positive results from a clinical study confirming the safety and potential of the treatment, the donation will help Bert and his team develop a second generation of these stem cells. This next step aims to further improve the therapy and support the requirements needed for clinical implementation.

Ultimately, the goal is to bring this innovative treatment closer to patients and, in the longer term, towards clinical availability and reimbursement through health insurance.